NASDAQ:HPTX »
-
Company News » Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Hyperion Therapeutics, Inc. StockholdersBusiness Wire - September 10, 2014, 22:57 GMT
Kirby McInerney LLP is investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. (“Hyperion” or the “Company”) (NASDAQ:HPTX) concerning the termination of the development of its Type 1 diabetes drug due to the manipulation of trial data. On September 8, 2014, the Company announced that it is terminating development of DiaPep277 for
-
Company News » EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Hyperion Therapeutics, Inc. — HPTXBusiness Wire - September 8, 2014, 17:39 GMT
The Rosen Law Firm, P.A. announces that it is investigating potential securities claims against Hyperion Therapeutics, Inc. (NASDAQ:HPTX) resulting from allegations that the Company may have issued materially false statements to investors. On September 8, 2014, Hyperion Therapeutics shocked the market when it announced that it would terminate the development of its diabetes drug, DiaPep277,
Forex Broker Spreads » |
|
Most Popular Articles » |
- Violin Memory and Arrow Electronics Sign North America Distribution Deal 1 view
- MACOM Introduces GaN Bias Controller and Sequence Module 1 view
- Growth Slows In Polish Manufacturing Sector 1 view
- Accenture Enhances Ocean Cargo Pricing Software to Help Carriers Better Serve Customers at Reduced Costs 1 view
- Moderate Easing In UK Inflation 1 view
- Apple breaks pressure point on Icahn buy-in 1 view
- Sharp Swing In Mexican Inflation 1 view
- UnitedHealthcare Community Plan of Ohio and Youngstown Office on Minority Health Host Citywide Baby Shower and Health Fair 1 view
- UK Personal Credit Increases 1 view
- Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to be Presented as a Late Breaking Presentation at the European Society of Paediatric Endocrinology Conference 1 view